$LLY

Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands

Analysts raised price targets for Eli Lilly and AbbVie as Medicare expands GLP-1 access. JPMorgan lifted Lilly to $1,400 from $1,300, citing Mounjaro and Zepbound strength. AbbVie targets were raised by multiple firms. From July 1, Medicare’s GLP-1 Bridge lowers Zepbound and Lilly’s Foundayo to about $50/month for eligible patients; Lilly guided FY revenue to $82B-$85B.

Original reporting
Published Jul 10, 2026, 6:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 10, 2026, 6:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands — source image
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

For LLY, the combination of a new JPMorgan target and a specific Medicare access expansion for its products (Zepbound and Foundayo) is a direct, time-sensitive catalyst. For ABBV, the Medicare policy is not directly linked to its products, so the impact is more indirect and driven by analyst PT changes.

02

Market read

Traders may reassess obesity-drug demand assumptions ahead of July 1 Medicare access expansion, with LLY receiving the most direct linkage to the policy and a fresh analyst upgrade.

03

What to watch

Analyst price targets can lag real-world uptake; actual utilization, payer restrictions beyond Bridge, and competitive GLP-1 pricing dynamics could temper the read-through.

Relevance 7/10Novelty 6/10Timing: after-hours/near-record-high context with Medicare policy effective July 1

Background

The article frames obesity-drug demand as accelerating due to a new Medicare GLP-1 Bridge initiative starting July 1, while highlighting fresh Wall Street price-target actions.

Company-level read

Ticker impact

$LLYBullishMedium confidence
Context

JPMorgan raised Eli Lilly’s price target to $1,400 from $1,300 and reiterated overweight as Medicare GLP-1 coverage expands for Zepbound and Foundayo.

Expected impact

Bullish bias, with upside skew if analysts continue to model higher Medicare-driven demand.

Evidence & confidence

The article ties a fresh analyst target change to a specific policy starting July 1 that lowers patient cost and expands eligible access.

$ABBVNeutralLow confidence
Context

The article notes AbbVie’s recent string of price target increases tied to its immunology franchise, alongside broader large-cap pharma strength.

Expected impact

Limited incremental upside versus LLY, unless further obesity read-through emerges.

Evidence & confidence

The Medicare policy described is for Zepbound and Lilly’s oral pill, while ABBV is discussed mainly via immunology-driven strength and analyst PT changes.

Market effects

Medicare GLP-1 Bridge access expansion reinforces demand expectations for obesity drugs, likely supporting sentiment across GLP-1-focused pharma.

Primarily US demand-side catalyst via Medicare coverage.

Could strengthen global investor appetite for obesity franchises, though the policy is US-specific.

Counterpoint

Medicare Bridge eligibility is expected to be much smaller than the full 20 million Medicare-patient addressable market, so near-term demand uplift may be less than bulls imply.

Key entities

  • Eli Lilly

    JPMorgan raised its price target to $1,400 from $1,300; Medicare GLP-1 Bridge makes Zepbound and its oral pill Foundayo available to eligible patients.

  • AbbVie

    Receives multiple analyst price-target increases in recent sessions, but the Medicare policy described is not attributed to AbbVie’s obesity exposure.

  • Medicare GLP-1 Bridge initiative

    Starting July 1, lowers patient cost for Zepbound and Foundayo to as little as $50 per month for eligible Medicare patients.

Related articles

$ABBVMed

Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?

AbbVie said its neuroscience franchise grew in 1H 2026, with sales of $6.1B, up 21.8% year over year on an operational basis. Vraylar led at $1.98B (+18.6%), with Ubrelvy $731M (+26.4%), Qulipta $646M (+39.2%), Botox $2.05B (+13.2%), and Vyalev $457M. AbbVie raised 2026 neuroscience guidance to about $12.7B (+$100M) and overall revenue to about $67.6B (+$300M). It expects an FDA decision on tavapadon for PD in 3Q 2026.

$LLYMedAI 8/10

Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger

The UK Medicines and Healthcare products Regulatory Agency approved Eli Lilly’s oral weight-loss drug orforglipron (Foundayo) for weight management and type 2 diabetes, making it Europe’s first such approval, according to the regulator. The article notes Foundayo is a pill, while Novo Nordisk’s Wegovy is also a pill in the UK and has food restrictions. It cites IQVIA obesity-medicine market growth to $92B in 2026.

$NVOMed

Novo Nordisk Escalates Weight-Loss War With Eli Lilly

Novo Nordisk CEO Mike Doustdar defended the company’s lawsuit against Eli Lilly over obesity-drug advertising. The dispute cites a head-to-head trial where Zepbound (10 mg/15 mg) patients lost 20.2% body weight vs Wegovy 13.7% over 72 weeks. Novo argues older Wegovy dosing was used and cites FDA approval of higher Wegovy dose on Mar 19, 2026. Lilly said it backs its ads; Zepbound Q2 U.S. revenue rose 44% to $4.9B.